Dynavax Technologies Investigated for Sale to Sanofi at $15.50 per Share
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 30 2025
0mins
Should l Buy SNY?
Source: Businesswire
- Transaction Investigation: Kahn Swick & Foti LLC is investigating the proposed sale of Dynavax Technologies to Sanofi, where shareholders are set to receive $15.50 per share, raising questions about whether this price adequately reflects the company's true value.
- Legal Rights Consultation: Shareholders who believe the transaction undervalues Dynavax can seek no-obligation legal advice from Kahn Swick & Foti, aimed at protecting their rights and ensuring transparency in the sale process.
- Transaction Structure: The acquisition is structured as a tender offer, indicating that timing may be critical, and shareholders need to respond promptly to safeguard their interests.
- Former Attorney General Involvement: The involvement of former Louisiana Attorney General Charles C. Foti, Jr. in this investigation underscores the law firm's commitment to scrutinizing the transaction and advocating for shareholder rights.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SNY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SNY
Wall Street analysts forecast SNY stock price to rise
5 Analyst Rating
2 Buy
3 Hold
0 Sell
Moderate Buy
Current: 47.600
Low
57.00
Averages
79.36
High
119.07
Current: 47.600
Low
57.00
Averages
79.36
High
119.07
About SNY
Sanofi SA is a France-based healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sanofi's Lunsekimig Phase 2 Trials Show Promising Results
- Significant Research Outcomes: Sanofi's lunsekimig successfully met its primary and key secondary endpoints in two phase 2 studies for chronic respiratory diseases, indicating its potential in treating moderate-to-severe asthma and chronic rhinosinusitis.
- Good Safety Profile: The drug was well tolerated across all studies, with an acceptable safety profile, laying a solid foundation for its future clinical applications and potentially attracting more patients for subsequent treatments.
- Multiple Studies Conducted: The AIRCULES and DUET studies achieved success in moderate-to-severe asthma and chronic rhinosinusitis, respectively, while the VELVET study did not meet its primary endpoint, highlighting the variability in treatment responses across different diseases.
- Future Presentation Plans: Sanofi plans to present detailed results from the AIRCULES, DUET, and VELVET studies at upcoming medical congresses, which will provide more data support for the industry and could enhance the market prospects for lunsekimig.
See More
Sanofi's Lunsekimig Shows Promise in Phase 2 Trials for Respiratory Conditions
- Significant Efficacy: Sanofi's Lunsekimig demonstrated a statistically significant reduction in asthma exacerbations and meaningful lung function improvements in the AIRCULES Phase 2b study for moderate-to-severe asthma, highlighting its potential as a novel treatment option for over 260 million asthma patients worldwide who often struggle with uncontrolled symptoms.
- Success in Sinusitis Study: In the DUET Phase 2a study, Lunsekimig achieved its primary endpoint by significantly improving nasal congestion, nasal polyp scores, and Lund-Mackay CT scores at Week 24 in patients with chronic rhinosinusitis with nasal polyps, indicating its effectiveness in related inflammatory conditions.
- Dual Mechanism Advantage: Lunsekimig is a pentavalent Nanobody designed to block two inflammatory drivers, TSLP and IL-13, which may provide additive benefits over existing treatments, particularly in addressing tissue damage associated with asthma and related diseases.
- Future Research Plans: Sanofi plans to present detailed results at upcoming medical congresses and continues to advance Lunsekimig through additional Phase 2 and Phase 3 studies, including the PERSEPHONE trial for moderate-to-severe asthma and the THESEUS trial for CRSwNP, aiming to further validate its efficacy and safety.
See More
Sanofi's Lunsekimig Achieves Key Clinical Trial Success
- Clinical Trial Results: Sanofi's lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies for asthma and CRSwNP, indicating its potential to offer new treatment options for patients with respiratory diseases.
- Dual-Target Mechanism: Lunsekimig is a novel bispecific NanobodyVHH composed of five linked antibody fragments designed to simultaneously block TSLP and IL-13, two critical drivers of inflammation that contribute to tissue damage in asthma and related conditions.
- Good Safety Profile: The drug was well tolerated in both studies, demonstrating an acceptable safety profile, which lays a solid foundation for its future clinical applications and may encourage more patients to participate in subsequent trials.
- Strategic Implications: Sanofi's head of research and development noted that these findings support lunsekimig's dual-targeting mechanism as a promising solution for respiratory disease management, highlighting its competitive advantage in the market.
See More
Sanofi Receives EU Authorization for Rezurock in Chronic GVHD
- Regulatory Progress: Sanofi's Rezurock has received conditional marketing authorization from the European Commission for treating chronic graft-versus-host disease, addressing a significant gap in treatment options for patients who have undergone multiple prior therapies without success.
- Clinical Trial Results: In the Phase 2 ROCKstar trial, Rezurock achieved a 74% overall response rate, demonstrating significant improvements in patients who had already received two to five systemic therapies, indicating its potential in chronic GVHD treatment.
- Global Market Recognition: Rezurock is already approved in the U.S., Canada, the U.K., and over 20 other countries, with more than 20,000 patients treated worldwide, showcasing its broad application and acceptance in the international market.
- Future Development Directions: Sanofi is evaluating Rezurock in additional age groups and potential new indications, including pediatric patients as young as one year old and individuals with chronic lung allograft dysfunction, further expanding its market potential.
See More
Sanofi's Rezurock Receives Conditional EU Approval
- Conditional Marketing Authorization: Sanofi's Rezurock (belumosudil) has received conditional marketing authorization from the European Commission for treating chronic graft-versus-host disease in adults and children aged 12 and older weighing at least 40 kg, marking a significant advancement for the company in this therapeutic area.
- Clinical Research Support: The approval is based on safety and efficacy results from several clinical studies and real-world evidence, demonstrating Rezurock's potential in treating chronic graft-versus-host disease and further enhancing Sanofi's product portfolio.
- International Approval Status: In addition to the EU, Rezurock is approved in 20 countries, indicating its recognition and acceptance in global markets, which could provide Sanofi with broader market opportunities.
- Stock Price Dynamics: Sanofi's shares closed at €81.90, down 0.11%, reflecting a cautious market attitude towards the new drug approval, which may influence investor expectations regarding the company's future growth.
See More
Sanofi's Amlitelimab Phase 3 Data Shows Promising Efficacy
- Clinical Trial Results: Sanofi's phase 3 studies, COAST 1, COAST 2, and SHORE, demonstrate that its experimental eczema drug, amlitelimab, meets key efficacy endpoints, showing progressively increasing efficacy without plateau at Week 24, indicating its potential in treating moderate-to-severe atopic dermatitis patients.
- Dosing Frequency Advantage: The data support a Q12W dosing regimen for amlitelimab, allowing patients to experience less frequent dosing, which enhances adherence and quality of life, addressing the urgent needs of moderate-to-severe atopic dermatitis patients.
- Medical Need Fulfillment: Despite existing medications, a significant medical gap remains for moderate-to-severe atopic dermatitis, and Sanofi's findings suggest that amlitelimab can effectively reduce disease severity and burdensome symptoms, further driving the demand for new treatment options.
- Strategic Implications: Sanofi plans to file for global regulatory approvals, which is expected to lay the groundwork for profitable growth over the next five years, and the successful launch of amlitelimab will significantly enhance the company's market position in the eczema treatment sector.
See More
Sanofi's Lunsekimig Phase 2 Trials Show Promising Results
- Significant Research Outcomes: Sanofi's lunsekimig successfully met its primary and key secondary endpoints in two phase 2 studies for chronic respiratory diseases, indicating its potential in treating moderate-to-severe asthma and chronic rhinosinusitis.
- Good Safety Profile: The drug was well tolerated across all studies, with an acceptable safety profile, laying a solid foundation for its future clinical applications and potentially attracting more patients for subsequent treatments.
- Multiple Studies Conducted: The AIRCULES and DUET studies achieved success in moderate-to-severe asthma and chronic rhinosinusitis, respectively, while the VELVET study did not meet its primary endpoint, highlighting the variability in treatment responses across different diseases.
- Future Presentation Plans: Sanofi plans to present detailed results from the AIRCULES, DUET, and VELVET studies at upcoming medical congresses, which will provide more data support for the industry and could enhance the market prospects for lunsekimig.
See More
Sanofi's Lunsekimig Shows Promise in Phase 2 Trials for Respiratory Conditions
- Significant Efficacy: Sanofi's Lunsekimig demonstrated a statistically significant reduction in asthma exacerbations and meaningful lung function improvements in the AIRCULES Phase 2b study for moderate-to-severe asthma, highlighting its potential as a novel treatment option for over 260 million asthma patients worldwide who often struggle with uncontrolled symptoms.
- Success in Sinusitis Study: In the DUET Phase 2a study, Lunsekimig achieved its primary endpoint by significantly improving nasal congestion, nasal polyp scores, and Lund-Mackay CT scores at Week 24 in patients with chronic rhinosinusitis with nasal polyps, indicating its effectiveness in related inflammatory conditions.
- Dual Mechanism Advantage: Lunsekimig is a pentavalent Nanobody designed to block two inflammatory drivers, TSLP and IL-13, which may provide additive benefits over existing treatments, particularly in addressing tissue damage associated with asthma and related diseases.
- Future Research Plans: Sanofi plans to present detailed results at upcoming medical congresses and continues to advance Lunsekimig through additional Phase 2 and Phase 3 studies, including the PERSEPHONE trial for moderate-to-severe asthma and the THESEUS trial for CRSwNP, aiming to further validate its efficacy and safety.
See More
Sanofi's Lunsekimig Achieves Key Clinical Trial Success
- Clinical Trial Results: Sanofi's lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies for asthma and CRSwNP, indicating its potential to offer new treatment options for patients with respiratory diseases.
- Dual-Target Mechanism: Lunsekimig is a novel bispecific NanobodyVHH composed of five linked antibody fragments designed to simultaneously block TSLP and IL-13, two critical drivers of inflammation that contribute to tissue damage in asthma and related conditions.
- Good Safety Profile: The drug was well tolerated in both studies, demonstrating an acceptable safety profile, which lays a solid foundation for its future clinical applications and may encourage more patients to participate in subsequent trials.
- Strategic Implications: Sanofi's head of research and development noted that these findings support lunsekimig's dual-targeting mechanism as a promising solution for respiratory disease management, highlighting its competitive advantage in the market.
See More
Sanofi Receives EU Authorization for Rezurock in Chronic GVHD
- Regulatory Progress: Sanofi's Rezurock has received conditional marketing authorization from the European Commission for treating chronic graft-versus-host disease, addressing a significant gap in treatment options for patients who have undergone multiple prior therapies without success.
- Clinical Trial Results: In the Phase 2 ROCKstar trial, Rezurock achieved a 74% overall response rate, demonstrating significant improvements in patients who had already received two to five systemic therapies, indicating its potential in chronic GVHD treatment.
- Global Market Recognition: Rezurock is already approved in the U.S., Canada, the U.K., and over 20 other countries, with more than 20,000 patients treated worldwide, showcasing its broad application and acceptance in the international market.
- Future Development Directions: Sanofi is evaluating Rezurock in additional age groups and potential new indications, including pediatric patients as young as one year old and individuals with chronic lung allograft dysfunction, further expanding its market potential.
See More
Sanofi's Rezurock Receives Conditional EU Approval
- Conditional Marketing Authorization: Sanofi's Rezurock (belumosudil) has received conditional marketing authorization from the European Commission for treating chronic graft-versus-host disease in adults and children aged 12 and older weighing at least 40 kg, marking a significant advancement for the company in this therapeutic area.
- Clinical Research Support: The approval is based on safety and efficacy results from several clinical studies and real-world evidence, demonstrating Rezurock's potential in treating chronic graft-versus-host disease and further enhancing Sanofi's product portfolio.
- International Approval Status: In addition to the EU, Rezurock is approved in 20 countries, indicating its recognition and acceptance in global markets, which could provide Sanofi with broader market opportunities.
- Stock Price Dynamics: Sanofi's shares closed at €81.90, down 0.11%, reflecting a cautious market attitude towards the new drug approval, which may influence investor expectations regarding the company's future growth.
See More
Sanofi's Amlitelimab Phase 3 Data Shows Promising Efficacy
- Clinical Trial Results: Sanofi's phase 3 studies, COAST 1, COAST 2, and SHORE, demonstrate that its experimental eczema drug, amlitelimab, meets key efficacy endpoints, showing progressively increasing efficacy without plateau at Week 24, indicating its potential in treating moderate-to-severe atopic dermatitis patients.
- Dosing Frequency Advantage: The data support a Q12W dosing regimen for amlitelimab, allowing patients to experience less frequent dosing, which enhances adherence and quality of life, addressing the urgent needs of moderate-to-severe atopic dermatitis patients.
- Medical Need Fulfillment: Despite existing medications, a significant medical gap remains for moderate-to-severe atopic dermatitis, and Sanofi's findings suggest that amlitelimab can effectively reduce disease severity and burdensome symptoms, further driving the demand for new treatment options.
- Strategic Implications: Sanofi plans to file for global regulatory approvals, which is expected to lay the groundwork for profitable growth over the next five years, and the successful launch of amlitelimab will significantly enhance the company's market position in the eczema treatment sector.
See More
